These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23148794)

  • 41. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
    Park DW; Ahn JM; Song HG; Lee JY; Kim WJ; Kang SJ; Yun SC; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Am Heart J; 2013 Jan; 165(1):34-42.e1. PubMed ID: 23237131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
    Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725
    [No Abstract]   [Full Text] [Related]  

  • 44. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
    Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
    Good RI; McGarrity A; James TE; Miller H; McConnachie A; Goodall AH; Oldroyd KG
    Thromb Res; 2015 Jun; 135(6):1140-6. PubMed ID: 25746368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
    Price MJ; Angiolillo DJ; Teirstein PS; Lillie E; Manoukian SV; Berger PB; Tanguay JF; Cannon CP; Topol EJ
    Circulation; 2011 Sep; 124(10):1132-7. PubMed ID: 21875913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
    Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of clopidogrel response on the clinical evolution in patients with acute coronary syndromes.
    Costache II; Rusu C; Ivanov I; Popescu R; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):962-7. PubMed ID: 23700873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
    Liu YP; Hao PP; Zhang MX; Zhang C; Gao F; Zhang Y; Chen YG
    Thromb Res; 2011 Dec; 128(6):593-4. PubMed ID: 21794898
    [No Abstract]   [Full Text] [Related]  

  • 52. [Clopidogrel resistance--risk factor in patients with acute coronary syndromes].
    Costache Il; Rusu C; Ivanov I; Popescu R; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):383-8. PubMed ID: 23077924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High platelet reactivity and clinical outcome - fact and fiction.
    Sibbing D; Byrne RA; Bernlochner I; Kastrati A
    Thromb Haemost; 2011 Aug; 106(2):191-202. PubMed ID: 21505714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
    Mirzaev KB; Rytkin E; Ryzhikova KA; Grishina EA; Sozaeva ZA; Fedorinov DS; Konova OD; Giliarov MI; Belyakova GA; Andreev DA; Sychev DA
    Drug Metab Pers Ther; 2018 Sep; 33(3):109-118. PubMed ID: 30171809
    [No Abstract]   [Full Text] [Related]  

  • 55. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Geisler T; Bigalke B; Schwab M
    N Engl J Med; 2011 Feb; 364(5):481; author reply 482. PubMed ID: 21288102
    [No Abstract]   [Full Text] [Related]  

  • 56. Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism.
    Marziliano N; Notarangelo MF; Cereda M; Caporale V; Coppini L; Demola MA; Guidorossi A; Crocamo A; Pigazzani F; Boffetti F; del Giudice F; Orsini F; Pirola D; Cocci A; Manzalini C; Casu G; Bianchessi M; Ardissino D; Merlini PA
    Clin Chim Acta; 2015 Dec; 451(Pt B):240-6. PubMed ID: 26453416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans.
    Zhang HZ; Kim MH; Guo LZ; Serebruany V
    Blood Coagul Fibrinolysis; 2017 Jan; 28(1):56-61. PubMed ID: 27380588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.
    Mirzaev KB; Samsonova KI; Potapov PP; Andreev DA; Grishina EA; Ryzhikova KA; Sychev DA
    Mol Biol Rep; 2019 Aug; 46(4):4195-4199. PubMed ID: 31102151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome.
    Peng L; Zhang L; Yang J; Wang X; Li X; Guo W; Zhang Y; Xu Q; Lu C; Yin T
    Int J Cardiol; 2015 Feb; 180():196-8. PubMed ID: 25463363
    [No Abstract]   [Full Text] [Related]  

  • 60. CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center.
    Teixeira R; Monteiro P; Marques G; Pego J; Lourenço M; Tavares C; Reboredo A; Monteiro S; Gonçalves F; Ferreira MJ; Freitas M; Ribeiro G; Providência LA
    Rev Port Cardiol; 2012 Apr; 31(4):265-73. PubMed ID: 22377481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.